Late-perimenopauseNutriAgeNCT07378787
Time-Restricted Eating in Combination With a Low Glycaemic Index Diet on Cognitive Function, Biological Ageing and Metabolic Health in Perimenopause and Menopause.
A study testing Time-Restricted Low-Glycaemic Index Diet in people with Late-perimenopause and Menopause, run by University of Nicosia at 2 sites in 2 countries.
Trial summary
The goal of this randomised controlled trial is to investigate whether Time-Restricted Eating (TRE) combined with a Low Glycaemic Index Mediterranean Diet can improve cognitive function, metabolic health, and biological ageing in late perimenopausal and menopausal women aged 45-75 years with a BMI ≥23 kg/m². Read more about this study
- Who is it for?
- Ages 45 to 75 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Late-perimenopause, Menopause, Perimenopause
- What is being tested?
- Time-Restricted Low-Glycaemic Index Diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 72 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 17 Jan 2026to 20 Jan 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 75 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Women in late perimenopausal or menopausal status Note: Late perimenopause is defined as two or more skipped cycles and at least 60 days of amenorrhea. Recent blood tests showing elevated FSH levels support eligibility for late perimenopause. Menopause is defined as 12 consecutive months without a menstrual cycle.
- BMI ≥23 kg/m2
- Age 45-75 years old
- If using any medication, the dose should be stable for the previous 12 months
- Able to use technology and follow the dietary plan
Who cannot join
- Diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD). Note: (Self-reported memory complaints are allowed).
- On hormone replacement therapy (HRT)
- Medical conditions that significantly affect cognitive or metabolic function including diagnosis of type 1 diabetes, severe metabolic disorders, cardiovascular disease, or neurodegenerative conditions, diagnosed eating disorders or severe mental health conditions.
- Currently enrolled in another intervention.
- Severe food allergies or dietary restrictions that would prevent adherence to the study diet.
- History of substance abuse.
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
Francesco Colelli, MSc contact
2 sites in 2 countries
Cyprus1 site, 1 recruiting
- Recruiting
University of Nicosia
Nicosia, Engomi, 1700
Elena Philippou, PhD, +35799611272, philippou.e@unic.ac.cy
Fransesco Colelli, MSc, francesco92colelli@gmail.com
About this study
Official title: The Effect of Time-Restricted Eating in Combination With a Low Glycaemic Index Diet on Cognitive Function, Markers of Biological Age and Metabolic Health in Late-Perimenopausal and Menopausal Women: a Randomized Controlled Trial. The NutriAge Trial.
The goal of this randomised controlled trial is to investigate whether Time-Restricted Eating (TRE) combined with a Low Glycaemic Index Mediterranean Diet can improve cognitive function, metabolic health, and biological ageing in late perimenopausal and menopausal women aged 45-75 years with a BMI ≥23 kg/m². It will consist of a 12-week intervention followed by a 12 week follow-up period.
Researchers will compare a group following the 16:8 time-restricted eating schedule and Low Glycaemic Index Mediterranean Diet to a control group (waiting list) receiving no dietary or meal-timing instructions to determine if these dietary strategies influence cognitive function, assessed via brain-derived neurotropic factor (BDNF) and cognitive function tests, metabolic outcomes, biological age, the gut microbiome, tender and swollen joint count and global health.
Read more
Participants will:
Follow a 16:8 time-restricted eating schedule (eating within an 8-hour window and fasting for 16 hours) if assigned to the intervention group.
Adhere to a tailored Low Glycaemic Index Mediterranean Diet and track meals using the Nutrium app.
Attend study visits at the University of Nicosia at Week 0, Week 12, and Week 24 for various assessments.
Provide biological samples, including blood samples at five specific intervals and stool samples at Week 0 and Week 12.
Complete multiple questionnaires regarding diet, lifestyle, sleep quality, physical activity, tender and swollen joints, and quality of life.
Undergo physical and cognitive assessments, such as CNS Vital Signs tests, blood pressure measurements, and body composition analysis.
The two groups will be compared to understand if the intervention improves outcomes and can thus be applied in this population group.
Read the detailed description
This randomized controlled trial will run over a period of 24 weeks (6 months) and will be divided into two main phases: a 12-week intervention phase followed by a 12- week follow-up phase designed to assess long-term adherence and health outcomes. The participants will be randomized to one of two groups: the intervention group of a Time-Restricted Eating combined with a Low Glycaemic Index diet (TRE-LGI) group, and the control group which will not receive any dietary intervention.
During the intervention phase (Week 0 to Week 12), participants randomized to the TRE-LGI group will follow a structured eating plan. They will be instructed to consume all their meals within an 8-hour eating window each day and adhere to a low glycaemic index Mediterranean-style diet. Participants randomized to the control group will not receive any dietary intervention but will continue to be monitored for study purposes.
Assessments will be conducted at three time points during this phase. At baseline (Week 0), participants will complete a full set of evaluations, including the online Computerised Neurocognitive Testing tool CNS Vital Signs, metabolic markers (insulin sensitivity, and lipid profiles, C-reactive protein (CRP), BDNF assessment using Enzyme-Linked Immunosorbent Assay (ELISA) Test, biological ageing assessment using the N-glycome analysis (GlycanAge test), gut microbiome analysis from stool samples, body composition, blood pressure, waist circumference, sleep quality using the Pittsburgh Sleep Quality Index (PSQI), physical activity using the International Physical Activity Questionnaire-Short Form IPAQ-SF, tender and swollen joint count and Global Health using the PROMIS® Scale v1.2 - Global Health.
At Week 6, only the N-glycome composition analysis (GlycanAge) will be repeated to monitor changes in biological ageing.
At Week 12, all baseline assessments will be repeated to measure the effects of the intervention.
The follow-up phase, spanning from week 12-24, will focus on evaluating the participants' ability to sustain the dietary practices achieved during the intervention period without receiving further active dietary guidance. Monitoring will continue to measure the longer-term effects on cognitive, metabolic, and biological health outcomes.
At Week 18, participants will undergo N-glycome composition analysis (GlycanAge) to continue monitoring biological ageing.
At Week 24, a final comprehensive assessment will be conducted, including cognitive function (CNS Vital Signs), BDNF Test, N-glycome analysis, body composition using BIA, BMI, blood pressure, waist circumference, and sleep quality (PSQI), physical activity (IPAQ-SF), tender and swollen joint count, and Global Health PROMIS questionnaire.
Participants in the control group will complete the same assessments at each scheduled time point, allowing for direct comparisons; however, they will not undergo any dietary intervention throughout the study.
- Conditions
- Late-perimenopause, Menopause, Perimenopause
- Being tested
- Time-Restricted Low-Glycaemic Index Diet
- Keywords
- Peri-menopause, menopause, intermittent fasting, low glycaemic-index diet, women, time-restricted eating, biological ageing, metabolic markers, cognitive function, cognition, tender joints, swollen joints, nutrition, microbiome, Mediterranean diet, GlycanAge, randomized controlled trial, BDNF, insulin resistance, middle-aged
- Medical subject headings
- Intermittent Fasting, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Time-Restricted Low-Glycaemic Index DietOther
Also called intermittent fasting, low glycaemic diet, Mediterranean diet, 16:8
The combination of a 16:8 Time-Restricted eating period with a low glycaemic index Mediterranean diet
| Study group | Role | What they receive |
|---|---|---|
| Time-Restricted Low Glycaemic Index Diet | Experimental | Participants in the Time-Restricted-Low-Glycaemic Index group will follow a 16:8 intermittent fasting regimen, where all meals are consumed within an 8-hour eating window. Their diet will also consist of low-glycaemic index foods following the principles of the Mediterranean diet. They will provided with individualized dietary plans through the Nutrium App and followed up regularly through the app. Receives: Other: Time-Restricted Low-Glycaemic Index Diet |
| Control group | No intervention | The Control Group will receive no dietary intervention during the 6-month trial but will be placed on a waiting list for future guidance if requested. Their dietary intake will be recorded through the Nutrium App. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Brain-derived neurotrophic factor concentration
Changes between the intervention and control group in the concentration of brain-derived neurotrophic factor assessed by Enzyme-linked Immunosorbent Assay
Measured: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Secondary outcomes (12)
Cognitive function
Cognitive function using CNS Vital Signs assessments, including visual, verbal and composite memory, reaction time, executive function, complex attention and cognitive flexibility
Measured: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Insulin resistance
Fasting glucose and insulin to assess insulin resistance using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).
Measured: Week 0 and Week 12 for the intervention period
Lipid profile
Total cholesterol, LDL and HDL cholesterol, Triglyceride concentration, the triglyceride-to-HDL (TG/HDL) ratio will be calculated as a predictive marker for cardiovascular risk
Measured: Week 0 and Week 12 for the intervention period
C-reactive protein (CRP)
CRP concentration to assess inflammation
Measured: Week 0 and Week 12 for the intervention period
IgG N-glycome composition analysis to assess GlycanAge
The IgG N-glycome composition analysis will be used to measure biological ageing and systemic inflammation by analysing glycans attached to immunoglobulin G (IgG) antibodies in participants' blood samples using high-performance liquid chromatography (HPLC).
Measured: The test will be conducted at Week 0, 6, 12, 18, and 24 to monitor progressive changes in biological ageing throughout the 6-month study period.
Anthropometric measurements: Body weight, height, and calculation of the Body Mass Index
Body weight will be measured using minimal clothing. Height will be measured using a standard stadiometer. BMI will be calculated as weight in kg divided by height in metres squared
Measured: Week 0 and weekly thereafter until Week 24 for body weight and BMI, Week 0: Body height
Body composition analysis using Bioelectrical Impedance Analysis
Body composition analysis using Bioelectrical Impedance Analysis in the fasted state to assess % body fat, body fat mass, fat-free mass, skeletal muscle mass and visceral fat
Measured: Week 0 and Week 12 for the intervention phase and Week 24 for the follow-up phase
Gut microbiome
Gut microbiome will be assessed by performing phyla-level PCR analysis on the stool sample
Measured: Week 0 and Week 12 for the intervention period
Blood pressure
Blood pressure will be assessed using standard methods
Measured: Week 0 and Week 12 of the intervention period and Week 24 of the follow-up period
Sleep duration and quality
Subjective assessment of sleep duration and quality using the Pittsburgh Sleep Quality Index (PSQI)
Measured: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Tender and swollen joint count
The participant's number of tender and swollen joints will be self-assessed by providing a diagram to the participant, where they can mark any tender and/or swollen joints.
Measured: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Global Health
Global Health will be assessed using the PROMIS® Scale v1.2 - Global Health which evaluates key domains including global physical health, global mental health, physical function, fatigue, pain interference, emotional distress, social health, and quality of life through Likert-scale items.
Measured: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2026
- Study start17 Jan 2026
- Primary completion20 Jan 2029 (estimated)
- Study completion20 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Late-perimenopauseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled trial
- Masking
- None (open label)
- Enrolment
- 72 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Nicosia
- Sponsor type
- University, hospital or other
- Collaborators
- Digital Diet Clinic Ltd, GENOS LIMITED
- Responsible party
- Principal investigator, Elena Philippou, University of Nicosia
- Investigators
- Elena Philippou, PhD, Principal investigator, University of Nicosia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07378787
- Sponsor's protocol ID
- EEBK/EΠ/2025/52
- Acronym
- NutriAge
- Status last verified
- Jan 2026
- First submitted
- 23 Jan 2026
- Last updated
- 30 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data underlying the results reported in the published article (including cognitive test scores, metabolic markers, and N-glycome markers) will be made available to qualified researchers. Data will be shared only after a formal request and upon approval of a methodologically sound research proposal. To protect participant privacy in accordance with GDPR and the Cyprus National Bioethics Committee, all shared data will be coded, and researchers must sign a Data Use Agreement (DUA) ensuring they will not attempt to re-identify any individual.
Publications
Demetriou CA, Hileti D, Onisiphorou E, Kazafanioti C, Alogakos M, Vardakastani D, Christofidou E, Andreou EP, Giannaki CD, Stavrinou PS, Philippou P, Constantinidou F, Philippou E. Associations Between Chrono-Nutrition Behaviours and Cognitive Function in Middle-Aged Adults: The NUTRICO Cross-Sectional Cohort Study. Nutr Bull. 2025 Jun;50(2):262-277. doi: 10.1111/nbu.70000. Epub 2025 Feb 24.
PubMed 39992029
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Time-Restricted Eating in Combination With a Low Glycaemic Index Diet on Cognitive Function, Markers of Biological Age and Metabolic Health in Late-Perimenopausal and Menopausal Women: a Randomized Controlled Trial. The NutriAge Trial.
- ClinicalTrials.gov ID
- NCT07378787
- Acronym / sponsor ID
- NutriAge / EEBK/EΠ/2025/52
- Conditions
- Late-perimenopause, Menopause, Perimenopause
- Keywords
- Peri-menopause, menopause, intermittent fasting, low glycaemic-index diet, women, time-restricted eating, biological ageing, metabolic markers
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- University of NicosiaUniversity, hospital or other
- Collaborators
- Digital Diet Clinic Ltd, GENOS LIMITED
- Study start
- 17 Jan 2026 (actual)
- Primary completion
- 20 Jan 2029 (estimated)
- Study completion
- 20 Jan 2029 (estimated)
- First posted
- 30 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this randomised controlled trial is to investigate whether Time-Restricted Eating (TRE) combined with a Low Glycaemic Index Mediterranean Diet can improve cognitive function, metabolic health, and biological ageing in late perimenopausal and menopausal women aged 45-75 years with a BMI ≥23 kg/m². It will consist of a 12-week intervention followed by a 12 week follow-up period.
Researchers will compare a group following the 16:8 time-restricted eating schedule and Low Glycaemic Index Mediterranean Diet to a control group (waiting list) receiving no dietary or meal-timing instructions to determine if these dietary strategies influence cognitive function, assessed via brain-derived neurotropic factor (BDNF) and cognitive function tests, metabolic outcomes, biological age, the gut microbiome, tender and swollen joint count and global health.
Participants will:
Follow a 16:8 time-restricted eating schedule (eating within an 8-hour window and fasting for 16 hours) if assigned to the intervention group.
Adhere to a tailored Low Glycaemic Index Mediterranean Diet and track meals using the Nutrium app.
Attend study visits at the University of Nicosia at Week 0, Week 12, and Week 24 for various assessments.
Provide biological samples, including blood samples at five specific intervals and stool samples at Week 0 and Week 12.
Complete multiple questionnaires regarding diet, lifestyle, sleep quality, physical activity, tender and swollen joints, and quality of life.
Undergo physical and cognitive assessments, such as CNS Vital Signs tests, blood pressure measurements, and body composition analysis.
The two groups will be compared to understand if the intervention improves outcomes and can thus be applied in this population group.
Detailed description
This randomized controlled trial will run over a period of 24 weeks (6 months) and will be divided into two main phases: a 12-week intervention phase followed by a 12- week follow-up phase designed to assess long-term adherence and health outcomes. The participants will be randomized to one of two groups: the intervention group of a Time-Restricted Eating combined with a Low Glycaemic Index diet (TRE-LGI) group, and the control group which will not receive any dietary intervention.
During the intervention phase (Week 0 to Week 12), participants randomized to the TRE-LGI group will follow a structured eating plan. They will be instructed to consume all their meals within an 8-hour eating window each day and adhere to a low glycaemic index Mediterranean-style diet. Participants randomized to the control group will not receive any dietary intervention but will continue to be monitored for study purposes.
Assessments will be conducted at three time points during this phase. At baseline (Week 0), participants will complete a full set of evaluations, including the online Computerised Neurocognitive Testing tool CNS Vital Signs, metabolic markers (insulin sensitivity, and lipid profiles, C-reactive protein (CRP), BDNF assessment using Enzyme-Linked Immunosorbent Assay (ELISA) Test, biological ageing assessment using the N-glycome analysis (GlycanAge test), gut microbiome analysis from stool samples, body composition, blood pressure, waist circumference, sleep quality using the Pittsburgh Sleep Quality Index (PSQI), physical activity using the International Physical Activity Questionnaire-Short Form IPAQ-SF, tender and swollen joint count and Global Health using the PROMIS® Scale v1.2 - Global Health.
At Week 6, only the N-glycome composition analysis (GlycanAge) will be repeated to monitor changes in biological ageing.
At Week 12, all baseline assessments will be repeated to measure the effects of the intervention.
The follow-up phase, spanning from week 12-24, will focus on evaluating the participants' ability to sustain the dietary practices achieved during the intervention period without receiving further active dietary guidance. Monitoring will continue to measure the longer-term effects on cognitive, metabolic, and biological health outcomes.
At Week 18, participants will undergo N-glycome composition analysis (GlycanAge) to continue monitoring biological ageing.
At Week 24, a final comprehensive assessment will be conducted, including cognitive function (CNS Vital Signs), BDNF Test, N-glycome analysis, body composition using BIA, BMI, blood pressure, waist circumference, and sleep quality (PSQI), physical activity (IPAQ-SF), tender and swollen joint count, and Global Health PROMIS questionnaire.
Participants in the control group will complete the same assessments at each scheduled time point, allowing for direct comparisons; however, they will not undergo any dietary intervention throughout the study.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Time-Restricted Low Glycaemic Index Diet | Experimental | Other: Time-Restricted Low-Glycaemic Index DietParticipants in the Time-Restricted-Low-Glycaemic Index group will follow a 16:8 intermittent fasting regimen, where all meals are consumed within an 8-hour eating window. Their diet will also consist of low-glycaemic index foods following the principles of the Mediterranean diet. They will provided with individualized dietary plans through the Nutrium App and followed up regularly through the app. |
| Control group | No intervention | –The Control Group will receive no dietary intervention during the 6-month trial but will be placed on a waiting list for future guidance if requested. Their dietary intake will be recorded through the Nutrium App. |
Who may qualify
- Ages
- 45 to 75 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Women in late perimenopausal or menopausal status Note: Late perimenopause is defined as two or more skipped cycles and at least 60 days of amenorrhea. Recent blood tests showing elevated FSH levels support eligibility for late perimenopause. Menopause is defined as 12 consecutive months without a menstrual cycle.
- BMI ≥23 kg/m2
- Age 45-75 years old
- If using any medication, the dose should be stable for the previous 12 months
- Able to use technology and follow the dietary plan
Key exclusion criteria (6 listed)
- Diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD). Note: (Self-reported memory complaints are allowed).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Time-Restricted Low-Glycaemic Index DietAlso: intermittent fasting, low glycaemic diet, Mediterranean diet, 16:8The combination of a 16:8 Time-Restricted eating period with a low glycaemic index Mediterranean diet | Other | Time-Restricted Low Glycaemic Index Diet |
Primary outcome
Brain-derived neurotrophic factor concentration
Time frame: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Changes between the intervention and control group in the concentration of brain-derived neurotrophic factor assessed by Enzyme-linked Immunosorbent Assay
12 secondary outcomes
Cognitive function
Time frame: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Insulin resistance
Time frame: Week 0 and Week 12 for the intervention period
Lipid profile
Time frame: Week 0 and Week 12 for the intervention period
C-reactive protein (CRP)
Time frame: Week 0 and Week 12 for the intervention period
IgG N-glycome composition analysis to assess GlycanAge
Time frame: The test will be conducted at Week 0, 6, 12, 18, and 24 to monitor progressive changes in biological ageing throughout the 6-month study period.
Anthropometric measurements: Body weight, height, and calculation of the Body Mass Index
Time frame: Week 0 and weekly thereafter until Week 24 for body weight and BMI, Week 0: Body height
Body composition analysis using Bioelectrical Impedance Analysis
Time frame: Week 0 and Week 12 for the intervention phase and Week 24 for the follow-up phase
Gut microbiome
Time frame: Week 0 and Week 12 for the intervention period
Blood pressure
Time frame: Week 0 and Week 12 of the intervention period and Week 24 of the follow-up period
Sleep duration and quality
Time frame: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Tender and swollen joint count
Time frame: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Global Health
Time frame: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2026.
- Background: PubMed 39992029Demetriou CA, Hileti D, Onisiphorou E, Kazafanioti C, Alogakos M, Vardakastani D, Christofidou E, Andreou EP, Giannaki CD, Stavrinou PS, Philippou P, Constantinidou F, Philippou E. Associations Between Chrono-Nutrition Behaviours and Cognitive Function in Middle-Aged Adults: The NUTRICO Cross-Sectional Cohort Study. Nutr Bull. 2025 Jun;50(2):262-277. doi: 10.1111/nbu.70000. Epub 2025 Feb 24.
- Facebook page providing information on study recruitment and progressLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified individual participant data underlying the results reported in the published article (including cognitive test scores, metabolic markers, and N-glycome markers) will be made available to qualified researchers. Data will be shared only after a formal request and upon approval of a methodologically sound research proposal. To protect participant privacy in accordance with GDPR and the Cyprus National Bioethics Committee, all shared data will be coded, and researchers must sign a Data Use Agreement (DUA) ensuring they will not attempt to re-identify any individual.
Related trials for Late-perimenopause
Recruiting
Effects of a Dietary Supplement in Women With Late Perimenopause or Early Postmenopause
Perimenopause, Postmenopause
Recruiting
Prebiotic Inulin for Late-Reproductive Individuals
Obesity & Overweight, Perimenopausal Women
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Francesco Colelli, MSc contact
Elena Philippou, PhD principal investigator
University of Nicosia
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Time-Restricted Low-Glycaemic Index Diet in people with Late-perimenopause and Menopause, run by University of Nicosia at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Croatia, Cyprus. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Elena Philippou, PhD (+35799611272, philippou.e@unic.ac.cy), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Brain-derived neurotrophic factor concentration (time frame: Week 0 and Week 12 for the intervention period and Week 24 for the follow-up period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07378787, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2026.